Expiratory (breathing-out) muscle strength and health outcomes in bronchiectasis
Official title: Effect of Expiratory Muscle Strength on Hospital Admission, Disease Severity and Quality of Life in Patients With Bronchiectasis
Run by Saglik Bilimleri Universitesi · NCT07104942 · Data updated 2026-11-12
This project tests whether weaker expiratory (breathing-out) muscles are linked to worse symptoms, more hospital visits, and lower quality of life in adults with non‑cystic fibrosis bronchiectasis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 64 (estimated) |
| Sponsor | Saglik Bilimleri Universitesi Academic / other |
| Locations | 1 site (Istanbul) |
| Status | Recruiting |
| Started | August 2025 |
| Main results expected | December 2025 |
| Study ends | June 2026 |
| Registry record updated | August 24, 2025 |
| Trial ID | NCT07104942 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–65 with a confirmed diagnosis of non‑cystic fibrosis bronchiectasis who are not experiencing an acute infection at the time of assessment are ideal candidates.
✕Probably not a fit
People with cystic fibrosis, active respiratory infection, pregnancy, myopathies, recent stroke, or unstable cardiac disease are unlikely to benefit from or be eligible for this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will measure expiratory muscle strength in adults with non‑cystic fibrosis bronchiectasis and relate those measurements to clinical outcomes including disease severity, history of hospital admissions, cough effectiveness, and quality of life. Participants aged 18–65 without an acute infection will undergo respiratory muscle testing and clinical data collection. The study is conducted at a single chest diseases center in Istanbul and will use the findings to explore whether expiratory muscle weakness contributes to impaired airway clearance. Results are intended to inform future interventional research in pulmonary rehabilitation and respiratory muscle training.
Why it matters
Potential benefit: If expiratory muscle weakness is identified as a contributor to worse outcomes, targeted physiotherapy or respiratory muscle training could be developed to improve cough effectiveness, symptoms, and possibly reduce hospitalizations.
How similar studies have gone: Respiratory muscle training has shown benefits in other chronic lung diseases, but clear evidence specifically linking expiratory muscle strength to outcomes in bronchiectasis is limited and this application is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Having a diagnosis of non-cystic fibrosis bronchiectasis * Without an acute infection at the time of assessment (confirmed by medical history, serum C-reactive protein levels, chest X-ray and/or HRCT). * Being between 18 and 65 years of age Exclusion Criteria: * Myopathies * Stroke (Cerebrovascular accident - CVA) * Pregnancy * Unstable cardiac disease
Where it's running
-
Süreyyapaşa Chest Diseases and Chest Surgery Training and Research Hospital
Istanbul, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Nisanur Tutuş
- Email: nisanurtutuss@gmail.com
- Phone: (0216) 421 42 00
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
Breathlessness in respiratory diseases: who feels it and why
This study tests how physiology, psychology, function, and breathing patterns relate to breathlessness in people with respiratory conditions compared with healthy controls.
-
Hypertonic saline inhalation for NTM lung disease
This trial tests whether starting inhaled 3% hypertonic saline early helps people with non-tuberculous mycobacterial lung disease feel better and clear bacteria better, compared with starting with normal saline first.
-
Azithromycin added to usual care to see if it lowers bronchiectasis flare-ups
This trial tests whether taking azithromycin daily for a year reduces bronchiectasis-related flare-ups in adults with non-cystic fibrosis bronchiectasis.
-
Bronchiectasis Phenotype Identification Model for Adults
This study tests a baseline classifier to categorize adults with non-cystic fibrosis bronchiectasis into phenotype groups using data collected over time.
-
BASE: Aiming to test a simple, objective way to gauge bronchiectasis severity and predict flare-ups
This study tests a new BASE framework to classify how severe non-cystic fibrosis bronchiectasis is right now and see if it can predict 12 months of worsening or flare-ups.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.